{"id":"sodium-aurothiomalate","rwe":[{"pmid":"41230800","year":"2025","title":"The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.","finding":"","journal":"FEBS letters","studyType":"Clinical Study"},{"pmid":"36655064","year":"2022","title":"Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions.","finding":"","journal":"Case reports in dermatology","studyType":"Clinical Study"},{"pmid":"34662569","year":"2022","title":"The thyroid hormone converting enzyme human deiodinase 1 is inhibited by gold ions from inorganic salts, organic substances, and by small-size nanoparticles.","finding":"","journal":"Chemico-biological interactions","studyType":"Clinical Study"},{"pmid":"34114261","year":"2021","title":"Inclusion Complexes of Gold(I)-Dithiocarbamates with β-Cyclodextrin: A Journey from Drug Repurposing towards Drug Discovery.","finding":"","journal":"Chemistry (Weinheim an der Bergstrasse, Germany)","studyType":"Clinical Study"},{"pmid":"33652341","year":"2021","title":"In-vitro and in-vivo monitoring of gold(III) ions from intermediate metabolite of sodium aurothiomalate through water-soluble ruthenium (II) complex-based luminescent probe.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"sodium aurothiomalate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tyrosine-protein kinase Fyn","category":"target"},{"label":"FYN","category":"gene"},{"label":"ADORA3","category":"gene"},{"label":"EGFR","category":"gene"},{"label":"M01CB01","category":"atc"},{"label":"Active","category":"status"},{"label":"Juvenile rheumatoid arthritis","category":"indication"},{"label":"Rheumatoid arthritis","category":"indication"},{"label":"Antirheumatic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1067.427,"date":"","count":531,"signal":"Red blood cell sedimentation rate increased","source":"DrugCentral FAERS","actionTaken":"Reported 531 times (LLR=1067)"},{"llr":1006.998,"date":"","count":915,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 915 times (LLR=1007)"},{"llr":898.66,"date":"","count":857,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 857 times (LLR=899)"},{"llr":830.095,"date":"","count":1000,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 1,000 times (LLR=830)"},{"llr":825.971,"date":"","count":996,"signal":"Joint swelling","source":"DrugCentral FAERS","actionTaken":"Reported 996 times (LLR=826)"},{"llr":799.664,"date":"","count":634,"signal":"C-reactive protein increased","source":"DrugCentral FAERS","actionTaken":"Reported 634 times (LLR=800)"},{"llr":751.933,"date":"","count":265,"signal":"Blood parathyroid hormone decreased","source":"DrugCentral FAERS","actionTaken":"Reported 265 times (LLR=752)"},{"llr":735.085,"date":"","count":251,"signal":"Granuloma skin","source":"DrugCentral FAERS","actionTaken":"Reported 251 times (LLR=735)"},{"llr":712.78,"date":"","count":266,"signal":"Panniculitis","source":"DrugCentral FAERS","actionTaken":"Reported 266 times (LLR=713)"},{"llr":702.283,"date":"","count":904,"signal":"Drug intolerance","source":"DrugCentral FAERS","actionTaken":"Reported 904 times (LLR=702)"},{"llr":666.4,"date":"","count":283,"signal":"Rheumatoid nodule","source":"DrugCentral FAERS","actionTaken":"Reported 283 times (LLR=666)"},{"llr":635.038,"date":"","count":377,"signal":"C-reactive protein abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 377 times (LLR=635)"},{"llr":634.002,"date":"","count":1907,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 1,907 times (LLR=634)"},{"llr":559.983,"date":"","count":248,"signal":"Skin necrosis","source":"DrugCentral FAERS","actionTaken":"Reported 248 times (LLR=560)"},{"llr":512.481,"date":"","count":688,"signal":"Rheumatoid arthritis","source":"DrugCentral FAERS","actionTaken":"Reported 688 times (LLR=512)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=sodium aurothiomalate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:14:50.665894+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:14:57.051685+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sodium aurothiomalate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:14:57.372984+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL306043/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:14:58.697453+00:00"}},"allNames":"aurolate","offLabel":[],"synonyms":["sodium aurothiomalate","aurolate","aurothiomalate sodium","gold sodium thiomalate","sodium aurithiomalate","myochrysine"],"timeline":[{"date":"1992-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1992-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Aurolate","ecosystem":[{"indication":"Juvenile rheumatoid arthritis","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"etodolac","slug":"etodolac","company":"Wyeth Pharms Inc"}],"globalPrevalence":18000000},{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"target":"Tyrosine-protein kinase Fyn","targets":[{"gene":"FYN","source":"DrugCentral","target":"Tyrosine-protein kinase Fyn","protein":"Tyrosine-protein kinase Fyn"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"CTSL","source":"DrugCentral","target":"Cathepsin L1","protein":"Cathepsin L1"},{"gene":"TXNRD1","source":"DrugCentral","target":"Thioredoxin reductase 1, cytoplasmic","protein":"Thioredoxin reductase 1, cytoplasmic"}],"modality":"Small Molecule","drugClass":"sodium aurothiomalate","explanation":"","oneSentence":"","technicalDetail":"Aurolate binds to the ATP-binding site of tyrosine-protein kinase Fyn, thereby inhibiting its activity and reducing the phosphorylation of downstream targets involved in inflammatory pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4706","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=sodium%20aurothiomalate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sodium aurothiomalate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:38:12.166383","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:00.377804+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"sodium aurothiomalate","indications":{"approved":[{"name":"Juvenile rheumatoid arthritis","source":"DrugCentral","snomedId":410795001,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[{"name":"Felty's syndrome","source":"DrugCentral","drugName":"sodium aurothiomalate"},{"name":"Psoriasis with arthropathy","source":"DrugCentral","drugName":"sodium aurothiomalate","evidenceCount":24,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01383668","phase":"PHASE1","title":"Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2011-06","conditions":["Recurrent Non-small Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":"2013-02-08"},{"nctId":"NCT00575393","phase":"PHASE1","title":"Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01-25","conditions":["Lung Cancer"],"enrollment":17,"completionDate":"2012-02-14"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000146340","MMSL":"2006","NDDF":"002396","UNII":"E4768ZY6GM","VUID":"4017995","CHEBI":"CHEBI:35864","VANDF":"4017995","INN_ID":"4154","RXNORM":"203004","UMLSCUI":"C0018034","chemblId":"CHEMBL306043","ChEMBL_ID":"CHEMBL306043","KEGG_DRUG":"D00992","DRUGBANK_ID":"DB09276","PUBCHEM_CID":"22318","SNOMEDCT_US":"387380005","MESH_DESCRIPTOR_UI":"D006052"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":305,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01CB01","allCodes":["M01CB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"41230800","title":"The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.","journal":"FEBS letters"},{"date":"2022 Sep-Dec","pmid":"36655064","title":"Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions.","journal":"Case reports in dermatology"},{"date":"2022 Jan 5","pmid":"34662569","title":"The thyroid hormone converting enzyme human deiodinase 1 is inhibited by gold ions from inorganic salts, organic substances, and by small-size nanoparticles.","journal":"Chemico-biological interactions"},{"date":"2021 Aug 19","pmid":"34114261","title":"Inclusion Complexes of Gold(I)-Dithiocarbamates with β-Cyclodextrin: A Journey from Drug Repurposing towards Drug Discovery.","journal":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"date":"2021 May","pmid":"33652341","title":"In-vitro and in-vivo monitoring of gold(III) ions from intermediate metabolite of sodium aurothiomalate through water-soluble ruthenium (II) complex-based luminescent probe.","journal":"Bioorganic chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1992-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:00.377804+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}